TIGER-1NCT07767110
Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response
StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Lead sponsor: NanOlogy, LLC to NanOlogy, LLC (doing business as Intryx Therapeutics, LLC)
- Eligibility criteria changed
- Secondary endpoints: details revised at 2 of 5 entries
- Notable Primary endpoint(s) modified
- Eligibility criteria expanded, about 51 words
- Secondary endpoints: details revised at 4 of 5 entries
- Study description expanded, about 7 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)
Timeframe: Day 1 to Week 24
Secondary (5)
Objective Response Rate (ORR)
Progression-Free Survival (PFS)
Overall Survival (OS)
Concentration of Cisplatin in the Systemic Circulation Post-infusion
Concentration of Cisplatin in the Cerebrospinal Fluid (CSF) Post-infusion
Arms and interventions
LSAM-Cisplatin 6 mg/mLExperimental
Phase 1 (Dose Escalation): Intratumoral infusion of LSAM-Cisplatin 6 mg/mL using sequential, dose escalating cohorts. Phase 2 (Dose Expansion): Intratumoral infusion of LSAM-Cisplatin 6 mg/mL at the recommended Phase 2 dose (RP2D).
Drugs: LSAM-Cisplatin